Cyprium Metals Ltd (ASX:CYM, OTC:CYPMF) has completed the sale of surplus generators from the Nifty Copper Complex in Western Australia. The company has received the final incremental payment of US$1.2 million (A$1.8 million), taking total proceeds to US$6.4 million (A$9.8 million).
The disposal program, previously flagged in company updates on 22 November 2024, 17 February 2025, 1 July 2025, 17 July 2025 and 31 October 2025, forms part of Cyprium’s phased restart plans for the Nifty operation.
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has moved to lock in the estimated US$75 million Canadian nerve repair market, appointing a second distributor to deliver full national coverage for its Remplir™ device.
The new Ontario-based partner has exclusive rights across Saskatchewan, Manitoba, Ontario, Quebec, New Brunswick, Nova Scotia, Prince Edward Island and Newfoundland, complementing Orthocell’s existing distributor in Alberta and British Columbia. With this split, Remplir becomes accessible to healthcare providers across both urban and rural Canada.
Synchronoss Technologies Inc (NASDAQ:SNCR) posted a profitable third quarter, driven by its recurring cloud software business.
Revenue for the quarter was $42 million, with 93.8% coming from recurring subscriptions, underscoring the stability of its SaaS-powered Personal Cloud platform.
Lisata Therapeutics Inc (NASDAQ:LSTA) has reported promising preclinical results suggesting its iRGD cyclic peptide, certepetide, could enhance the effectiveness of antibody-drug conjugates (ADCs) in cancer treatment.
The data, presented by Lisata’s licensing partner Catalent at the 16th Annual World ADC San Diego Conference, showed that certepetide may improve tumor penetration and broaden the distribution of cytotoxic agents within tumors.
AMC Entertainment Holdings (NYSE:AMC) is expected to surpass Wall Street estimates for its third quarter results, which are scheduled for release on Wednesday, Wedbush analysts believe.
The analysts see AMC posting revenue of $1.25 billion and adjusted EBITDA of $120 million, both above consensus estimates of $1.23 billion and $97 million, respectively.
Candel Therapeutics Inc (NASDAQ:CADL) will deliver three presentations at the upcoming 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
“Candel’s presentations at SITC 2025 exemplify our innovative approach to the discovery and development of novel immunotherapies,” said CEO Paul Peter Tak. “By leveraging next-generation research tools we are working to generate deep biological insights that inform every stage of drug development, from bench to bedside and back.”
North Bay Resources Inc. (OTC:NBRI) announced a weighted average of 3.38 ounces per ton of gold from its maiden ore shipment from the Fran Gold Project in British Columbia.
The update includes a re-assay of sample 25FRTB-5, which returned 6.62 ounces per ton gold using ALS Global’s Au-GRA21 method, the company highlighted.
374Water Inc (NASDAQ:SCWO) announced that it is processing the first phase of its award by the State of North Carolina for its Waste Destruction Services (WDS) to destroy Aqueous Film-Forming Foam (AFFF) utilizing its AirSCWO technology.
The provider of organic waste destruction technology and services said it will provide WDS to the University of North Carolina at Chapel Hill Collaboratory, with the first phase involving the treatment of 1,000 gallons of AFFF.
Ocean Power Technologies Inc (NYSE-A:OPTT) announced that it has been certified by the Association for Uncrewed Vehicle Systems International (AUVSI) as a Trusted Uncrewed Maritime Systems (UMS) Operator Training Provider.
The certification designates OPT as one of a select group of organizations authorized to deliver AUVSI-aligned operator training under the first industry-led framework for uncrewed maritime systems.
Midnight Sun Mining Corp (TSX-V:MMA, OTCQB:MDNGF) announced initial assay results, representing eight diamond drill holes, from the 2025 drilling campaign on the Kazhiba Main target at its flagship Solwezi Project in Zambia, which included 7.39% copper over 14.86 metres (m) from 17m to 31.86m depth in hole MSZ-25-029E.
The exploration company said drilling has intercepted new zones of “significant” oxide copper mineralization within the existing mineralized footprint.
Protalix Biotherapeutics Inc (NYSE-A:PLX) and Chiesi Global Rare Diseases said they have requested a re-examination of a recent negative opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) concerning a new dosing regimen for Elfabrio.
The CHMP’s opinion relates to a proposal to add a 2 mg/kg every-four-weeks (E4W) dosing option to the currently approved 1 mg/kg every-two-weeks (E2W) regimen for the treatment of adults with Fabry disease.
Sintana Energy Inc (TSX-V:SEI, OTCQB:SEUSF) has released a letter to shareholders providing additional details and context about its proposed all-share acquisition of Challenger Energy Group PLC (AIM:CEG, OTCQB:BSHPF), following the publication of a Scheme Document earlier in the day.
The document, available on Sintana’s website, outlines the elements of the acquisition and has been distributed to Challenger shareholders.
Power Metallic Mines Inc (TSX-V:PNPN, OTCQB:PNPNF) announced assay results from its summer drill program on the Lion Zone at its Nisk project in Quebec, which included 5.35 meters of 11.97% copper.
The Canadian exploration company said the summer drill program was designed to search for extensions to the Lion Zone, specifically down plunge from known mineralization, and to infill drill, including 'edge' holes, on the Lion zone to define the zone geometry to a confidence level that would allow a future mineral resource estimate to be carried out to an Indicated Resource classification.
Hydrogen Utopia International PLC (LSE:HUI, OTCQB:HUIPF) shares climbed 9% to 1.75p after the company announced it has been granted an Investment Registration Certificate by Saudi Arabia’s Ministry of Investment (MISA), giving it full legal status to operate in the Kingdom.
The approval allows Hydrogen Utopia to establish a branch or subsidiary in Saudi Arabia, hire staff, lease facilities and participate in both government and private-sector projects.
Lithium Universe Ltd (ASX:LU7, OTC:LUVSF) has successfully completed the first tranche of its $2.5 million share placement to sophisticated and professional investors, raising $2.46 million to accelerate development of its lithium refinery in Québec and solar-panel recycling technology in Australia.
The Tranche 1 shares — totalling 153.75 million at $0.016 each — were issued under the company’s existing placement capacity, representing a 2% premium to the 15-day volume-weighted average price (VWAP).
Anthracyclines like doxorubicin are among oncology’s most enduring drugs — but their power comes with a limit. Beyond a certain cumulative dose, the risk of irreversible heart damage rises sharply, forcing oncologists to cap or abandon otherwise effective treatments.
Race Oncology Ltd (ASX:RAC, OTC:RAONF) is trying to change that equation. Its lead candidate RC220 is being developed as both an anticancer and a cardioprotective therapy — a combination that could allow patients to receive doxorubicin for longer, or at higher doses, without the same risk of cardiac injury.